How to inject semaglutide safely comes down to three things: the medication belongs in subcutaneous tissue, the usual sites are the abdomen, front of the thigh, or back of the upper arm, and the exact spot should change each week. The abdomen site stays at least two inches from the navel. A brand device and a compounded vial are not interchangeable systems, so the instructions supplied with the prescribed product control every step. This article explains the shared principles, but it is not a substitute for the directions from the prescriber and dispensing pharmacy.
How to inject semaglutide: the safe sequence
A reliable routine begins by matching the medication in hand to its own label. The prescribed amount, concentration, device, storage conditions, and expected appearance all need to agree before an injection. Current Ozempic prescribing information describes once-weekly subcutaneous administration and directs users to a different injection spot each week within the same body region.
| Stage | What correct use looks like |
|---|---|
| Confirm | The medication name, prescribed amount, concentration or device strength, expiration date, and expected appearance all match the current label. |
| Select | The site is healthy subcutaneous tissue on the abdomen, front of a thigh, or back of an upper arm. |
| Prepare | Hands and the work surface are clean; the skin is cleaned as the product instructions specify and allowed to dry. |
| Deliver | The manufacturer or pharmacy directions for that exact pen, prefilled syringe, or vial-and-syringe system are followed from start to finish. |
| Finish | The used needle, syringe, or single-use device goes into an appropriate sharps container, and the site is noted so the next injection can move. |
A clinician or pharmacist should demonstrate the prescribed device before the first at-home use. That matters because some pens require a dose selector and a new pen needle, some devices contain one complete dose, and a compounded vial requires a separate syringe. A person who is unsure whether a full dose was delivered should contact the prescriber or pharmacy rather than repeat it.
Semaglutide injection sites
The three labeled regions offer enough room to rotate without inventing a fourth site. The current Wegovy instructions for use give the most specific boundaries: the lower abdomen at least two inches from the belly button, the front of either thigh, or the back of an upper arm. The arm can be difficult to reach and see, so its instructions anticipate help from another person.
| Site | Label-based boundary | Practical rotation |
|---|---|---|
| Abdomen | At least 2 inches from the navel | Move among separated spots across the left and right lower abdomen |
| Thigh | Front of the thigh | Alternate thighs or move to a clearly different point on the same thigh |
| Upper arm | Back of the upper arm | Use a spot that can be reached and seen safely; assistance may be needed |
None of the three is a secret stronger site. The Ozempic label reports similar exposure after injection in the abdomen, thigh, or upper arm. A pharmacokinetic analysis drawing on nine clinical pharmacology trials likewise found only minor differences in bioavailability between injection sites (Overgaard et al., Diabetes Therapy 2019). That makes comfort, visibility, and intact skin better reasons to choose among labeled sites than social-media claims about appetite or nausea.
For the same practical map applied to a different GLP-1 medicine, see where to inject tirzepatide. The medicines and devices differ, so that page is context rather than a substitute set of directions.
Why rotation matters
Rotation means changing the exact point of entry, not necessarily choosing a different body region every week. The same general area can be used when the new spot is distinct from the last one. This gives irritated tissue time to settle and reduces repeated trauma to one patch of skin.
The clearest clinical evidence comes from people who inject insulin much more frequently than semaglutide. In a six-month randomized trial, injection education that included moving away from lipohypertrophy, rotating within and between regions, and avoiding needle reuse improved technique and allowed insulin reductions without loss of overall glucose control (Chen et al., Diabetes Therapy 2021). That is not a semaglutide trial. It supports the general tissue-protection logic behind rotation, while the semaglutide labels supply the product-specific instruction.
Brand device versus compounded vial
A brand device arrives with manufacturer instructions built around that presentation. Depending on the product, it may be a multi-use pen with a dose selector, a single-dose pen, or a prefilled syringe. The prescribed dose is delivered through that device's own sequence.
A compounded vial is different. Medication is drawn into a separate syringe, and the pharmacy label specifies both the concentration and the volume that corresponds to the prescribed amount. Syringe units measure volume; they do not identify a semaglutide dose without the vial concentration. Directions copied from a pen, another vial, or an earlier refill can therefore produce the wrong amount. The FDA reports multiple adverse events, some requiring hospitalization, associated with measurement errors involving compounded injectable semaglutide in its GLP-1 safety update current through May 31, 2026.
Promise's semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA's compounding overview explains that compounded drugs do not undergo the agency's premarket review for safety, effectiveness, or quality. A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision belongs to the patient and the doctor. Compounded semaglutide explains that distinction in more depth.
What to avoid at the injection site
Tender, bruised, red, hard, scarred, or stretched skin is a poor injection target. So is the two-inch ring around the navel. Semaglutide is intended for the fatty layer beneath the skin, not a vein or muscle. When insulin is also used, Ozempic labeling permits both injections in the same body region but says they should remain separate, never mixed, and not adjacent.
A damaged device, an expired product, or medication that does not match the appearance described on its label calls for a pharmacy check before use. The brand instructions describe clear, colorless medicine, but a compounded formulation may have a different expected appearance based on its ingredients; its pharmacy label is the reference. Pens and needles are not shared, even with a new needle, and a needle is not reused.
Minor bleeding can happen. Product instructions generally describe light pressure with gauze rather than rubbing. Persistent swelling, warmth, spreading redness, drainage, severe pain, or repeated hard lumps deserve a call to the care team. Trouble breathing, facial or throat swelling, fainting, or another sign of a severe allergic reaction requires urgent medical help. Semaglutide side effects covers medication reactions beyond the mechanics of the injection.
Timing and the instructions that win
The approved Ozempic label describes use once weekly on the same day, at any time, with or without food. It also says the day may change when at least 48 hours separate two doses. Switching among the three labeled injection regions does not itself call for a dose adjustment. Other presentations have their own missed-dose and device instructions, and a compounded prescription may use different concentration wording. The current prescription label settles those details.
At Promise, a licensed provider reviews every request, and not everyone qualifies. When a prescription is written, the provider and partner pharmacy supply the product-specific amount, measurement, storage, and injection directions. Those instructions remain the source of truth when a general article, an older refill, or an online video says something different.
The safest routine is deliberately boring: the right product, the current label, healthy subcutaneous tissue, a new spot, and no guesswork about syringe markings.